October 2, 2010
Read the full press release from S.A.N.E.-Vax.org.
North Hollywood, CA, September 22, 2010 — An article posted on Sept. 3 in Infectious Disease News data presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy showed the quadrivalent human papillomavirus vaccine (Gardasil) did not raise the risk for developing autoimmune conditions. The study was sponsored by Merck and conducted on behalf of the Gardasil Safety Team.
Meanwhile back at the FDA Department of Health and Human Services, a letter was issued to GlaxoSmithKline Biologicals on September 2, 2010, granting “your request to supplement your biologics license application for Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant (Cervarix), to add lymphadenopathy to the Adverse Reactions, Postmarketing Experience section of the full prescribing information.”
S.A.N.E. Vax.org is asking: “Which one is it boys?”
According to Wikipedia, “lymphadenopathy is a term meaning “disease of the lymph nodes.” It is, however, almost synonymously used with “swollen/enlarged lymph nodes. It could be due to infection, auto-immune disease, or malignancy. Autoimmune etiology includes sarcoidosis, systemic lupus erythematosus, and rheumatoid arthritis all giving a generalized lymphadenopathy.“
To date, over 300 events have been reported to the Vaccine Adverse Event Reporting System (VAERS) where the vaccine is HPV or HPV4 (Gardasil) and the symptom is lymphadenopathy…
Norma Erickson, President of S.A.N.E Vax, Inc., referred to the latest Merck funded study on autoimmune diseases as “an outrageous excuse for a scientific study. There are over 60 autoimmune disorders reported to VAERS and the 16 least likely to exhibit (even with Gardasil) were chosen with percentages compiled on only 11 of those – and they were probably randomly sampled.”